title: Improvement in skin wrinkles using a preparation containing human growth factors and hyaluronic acid serum.
abstract: BACKGROUND
  Skin aging is accompanied by wrinkle formation. At some sites, such as the periorbital skin, this is a relatively early phenomenon.
  
  
  OBJECTIVE
  We evaluated the anti-wrinkle effect of a preparation containing human growth factor and hyaluronic acid serum on periorbital wrinkles (crow's feet).
  
  
  METHODS
  In total, 23 Korean women (age range: 39-59 years), who were not pregnant, nursing, or undergoing any concurrent therapy, were enrolled in this study. All the patients completed an 8-week trial of twice-daily application of human growth factor and hyaluronic acid serum on the entire face. Efficacy was based on a global photodamage score, photographs, and image analysis using replicas and visiometer analysis every 4 weeks. The standard wrinkle and roughness parameters used in assessing skin by visiometer were calculated and statistically analyzed.
  
  
  RESULTS
  Periorbital wrinkles were significantly improved after treatment, with improvements noted both by physician's assessment and visiometer analysis.
  
  
  CONCLUSIONS
  Topical application of human growth factor and hyaluronic acid was beneficial in reducing periorbital wrinkles.
authors.affiliation: Nutrex Technology R&D Center , Seoul , South Korea.
authors.forename: Do Hyun
authors.initials: DH
authors.lastname: Lee
authors.forename: In Young
authors.initials: IY
authors.lastname: Oh
authors.forename: Kyo Tan
authors.initials: KT
authors.lastname: Koo
authors.forename: Jang Mi
authors.initials: JM
authors.lastname: Suk
authors.forename: Sang Wook
authors.initials: SW
authors.lastname: Jung
authors.forename: Jin Oh
authors.initials: JO
authors.lastname: Park
authors.forename: Beom Joon
authors.initials: BJ
authors.lastname: Kim
authors.forename: Yoo Mi
authors.initials: YM
authors.lastname: Choi
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D004815:Epidermal Growth Factor / Q000627:therapeutic use; D005260:Female; D051526:Fibroblast Growth Factor 10 / Q000627:therapeutic use; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use*; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use; D036341:Intercellular Signaling Peptides and Proteins / Q000627:therapeutic use*; D008875:Middle Aged; D015595:Skin Aging / Q000187:drug effects*
chemical_list: D003879:Dermatologic Agents; D004338:Drug Combinations; C496463:FGF10 protein, human; D051526:Fibroblast Growth Factor 10; D036341:Intercellular Signaling Peptides and Proteins; D016222:Fibroblast Growth Factor 2; D004815:Epidermal Growth Factor; D007334:Insulin-Like Growth Factor I; D006820:Hyaluronic Acid
keywords: human growth factor; hyaluronic acid; wrinkle